2025 연구자 정보 (26 / 654)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Lee, Dong Ho (Lee, DH) |
Seoul Natl Univ, Coll Med, Dept Radiol, Seoul, South Korea Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam Si, South Korea |
|
|
[JCR상위 1.7%] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B [JCR상위 54.1%] A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis |
SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY |
pindra@empal.com leeoy@hanyang.ac.kr |
||
|
Lee, Han Ah (Lee, HA) |
Chung Ang Univ, Coll Med, Dept Internal Med, Seoul, South Korea |
|
|
[JCR상위 1.7%] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | pindra@empal.com | ||
|
Lee, Hyung-Chul (Lee, HC) |
Seoul Natl Univ, Coll Med, Dept Anesthesiol, Seoul, South Korea |
|
|
[JCR상위 1.7%] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | pindra@empal.com | ||
|
Lee, In Hee (Lee, IH) |
제1저자 | Daegu Catholic Univ, Sch Med, Dept Internal Med, Daegu, South Korea |
|
|
[JCR상위 1.7%] Real-time AI-based computer-aided detection/diagnosis (AI-CAD) for breast ultrasound: A prospective, multicenter, multinational study. [JCR상위 31.8%] Comparison of Urinary Red Blood Cell Distribution (URD) and Dysmorphic Red Blood Cells for Detecting Glomerular Hematuria: A Multicenter Study [JCR상위 1.7%] Role of EMP2 in triple-negative breast cancer. [JCR상위 1.7%] Predicting high-risk group according to Oncotype DX recurrence score using dynamic contrast-enhanced breast MR with temporal radiomic features. |
SCIE | 1.7 |
ONCOLOGY MEDICAL LABORATORY TECHNOLOGY |
chjeon@cu.ac.kr | |
|
Lee, Jeeyeon Elizabeth (Lee, JE) |
제1저자 |
|
|
[JCR상위 1.7%] Real-time AI-based computer-aided detection/diagnosis (AI-CAD) for breast ultrasound: A prospective, multicenter, multinational study. [JCR상위 1.7%] Role of EMP2 in triple-negative breast cancer. [JCR상위 1.7%] Predicting high-risk group according to Oncotype DX recurrence score using dynamic contrast-enhanced breast MR with temporal radiomic features. |
SCIE | 1.7 | ONCOLOGY | |||
|
Lee, Jeong-Hoon (Lee, JH) |
교신저자 |
Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea Seoul Natl Univ, Liver Res Inst, Coll Med, Seoul, South Korea Inocras Inc, San Diego, CA USA Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea |
|
|
[JCR상위 1.7%] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B [JCR상위 1.0%] Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION) interim results from a randomised controlled trial |
SCIE | 1.0 | GASTROENTEROLOGY & HEPATOLOGY |
pindra@empal.com limys@amc.seoul.kr |
|
|
Lee, Jieun (Lee, J) |
Samsung Elect, DRAM Yield Enhancement Team, Mfg & Proc Technol, Suwon 18448, Gyeonggi Do, South Korea |
|
|
[JCR상위 1.7%] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. [JCR상위 73.5%] Gate oxide technology relieving word-line break in 10 nm-class DRAMs |
SCIE | 1.7 |
ONCOLOGY PHYSICS, APPLIED |
yhong@pusan.ac.kr | ||
|
Lee, Keun Seok (Lee, KS) |
|
|
[JCR상위 1.7%] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. | SCIE | 1.7 | ONCOLOGY | ||||
|
Lee, Kyung-Hun (Lee, KH) |
|
|
[JCR상위 1.7%] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. | SCIE | 1.7 | ONCOLOGY | ||||
|
Lee, Soo Jung (Lee, SJ) |
|
|
[JCR상위 1.7%] Real-time AI-based computer-aided detection/diagnosis (AI-CAD) for breast ultrasound: A prospective, multicenter, multinational study. [JCR상위 1.7%] Role of EMP2 in triple-negative breast cancer. [JCR상위 1.7%] Predicting high-risk group according to Oncotype DX recurrence score using dynamic contrast-enhanced breast MR with temporal radiomic features. |
SCIE | 1.7 | ONCOLOGY | ||||
|
Lee, Suee (Lee, S) |
|
|
[JCR상위 1.7%] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. | SCIE | 1.7 | ONCOLOGY | ||||
|
Lim, Seungtaek (Lim, S) |
|
|
[JCR상위 1.7%] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. | SCIE | 1.7 | ONCOLOGY | ||||
|
Lin, Bingliang (Lin, BL) |
Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Peoples R China |
|
|
[JCR상위 1.7%] Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | jia_jd@ccmu.edu.cn | ||
|
Liu, Jie (Liu, J) |
Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Oncol, Jinan, Peoples R China |
|
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. [JCR상위 2.3%] Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report |
SCIE | 1.7 |
ONCOLOGY RESPIRATORY SYSTEM |
batel.blechter@nih.gov | ||
|
Loibl, Sibylle (Loibl, S) |
|
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY |
페이지 이동: